Zai Lab Limited ZLAB NASDAQ

Zai Lab Limited (ZLAB) reported total assets of $1.17B and total liabilities of $456.88M for fiscal year 2025, resulting in total equity of $715.5M.

The company held $689.57M in cash and short-term investments. Total debt stood at $224.26M, with net debt of $-455.31M. The Debt-to-Equity (D/E) ratio was 0.31 (conservative).

Current ratio is 2.45, indicating strong short-term liquidity. Interest coverage is -44x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (55/100) — Total assets $1.17B and equity $715.5M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.31 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 61/100 with 3/7 criteria passed.

ALNY

Alnylam Pharmaceuticals, Inc.

$339.41

+1.92%

SGEN

Seagen Inc.

$228.74

-0.07%

ROIV

Roivant Sciences Ltd.

$29.12

+0.59%

ASND

Ascendis Pharma A/S

$249.84

+0.52%

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%